Summary CUMYL-PINACA also referred to as SGT-24, belongs to the class of indazole-3-carboxamide synthetic cannabinoids. It is a robust agonist for cannabinoid receptors, demonstrating about threefold selectivity for CB1. Its affinity for human CB1 receptors is notably high, with an…
Summary CUMYL-4CN-BINACA, also known as CUMYL-CYBINACA or SGT-78, is an indazole-3-carboxamide-based synthetic cannabinoid that has been distributed online as a designer drug. This compound acts as a potent agonist for CB1 and CB2 cannabinoid receptors, with EC50 values of 0.58…
Summary APP-FUBINACA is a synthetic cannabinoid based on the indazole structure, and it has been distributed online as a designer drug. Regarding its pharmacological profile, research has indicated that APP-FUBINACA exhibits only moderate binding affinity for the CB1 receptor, with…
Summary APINACA, also known as AKB48 or N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, is a substance that functions as a reasonably potent agonist for cannabinoid receptors. It exhibits full agonist activity at the CB1 receptor, with an EC50 of 142 nM and a Ki of…
Summary AMB-CHMINACA, alternatively known as MMB-CHMINACA or MA-CHMINACA, belongs to the family of indazole-based synthetic cannabinoids. Notably, it exhibits strong agonistic activity towards the CB1 receptor and has entered the online market as a designer drug. Identifiers IUPAC name CAS…
Summary ADSB-FUB-187, an indazole-based synthetic cannabinoid, exhibits remarkable potency as a CB1 receptor agonist, boasting an impressively low binding affinity with a Ki value of 0.09 nM and an EC50 of 1.09 nM. Pfizer’s 2009 patent, WO 2009/106982, introduced this…
Summary ADB-PINACA, a cannabinoid designer drug, finds its place as a constituent in certain synthetic cannabis products. It stands out as a robust agonist of both the CB1 and CB2 receptors, boasting impressive EC50 values of 0.52 nM and 0.88…
Summary ADB-FUBINACA, a synthetic designer drug, initially surfaced in synthetic cannabis mixtures in Japan back in 2013. Notably, by 2018, it had risen to become the third most frequently detected synthetic cannabinoid in drug seizures by the Drug Enforcement Administration.The…
Summary ADB-CHMINACA, also recognized as MAB-CHMINACA, belongs to the class of indazole-based synthetic cannabinoids. Initially designed by Pfizer in 2009 for its potential as an analgesic medication, it stands out as a robust agonist of the CB1 receptor, boasting an…
Summary ADB-BINACA is a synthetic cannabinoid designer drug that has been identified as a component in certain synthetic cannabis formulations. Initially conceived by Pfizer for its potential analgesic properties, this compound is a robust agonist for the CB1 receptor, boasting…
